Artivion, Inc. (NYSE:AORT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Artivion, Inc. (NYSE:AORT) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $44.8333.

Several research firms have commented on AORT. Citizens Jmp lowered their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price target on shares of Artivion in a research report on Monday, July 20th. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Stifel Nicolaus set a $45.00 price objective on Artivion in a research note on Monday, June 1st.

Insider Buying and Selling at Artivion

In other Artivion news, CEO James P. Mackin sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the transaction, the chief executive officer owned 877,275 shares in the company, valued at $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 114,978 shares of company stock worth $2,965,155 over the last 90 days. Insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Artivion during the 2nd quarter worth $149,965,000. Vanguard Group Inc. boosted its holdings in Artivion by 4.7% during the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after acquiring an additional 141,030 shares during the period. Morgan Stanley grew its position in shares of Artivion by 0.8% in the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after purchasing an additional 18,248 shares during the last quarter. State Street Corp grew its position in shares of Artivion by 2.9% in the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after purchasing an additional 44,641 shares during the last quarter. Finally, Fred Alger Management LLC increased its stake in shares of Artivion by 4.2% in the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after purchasing an additional 55,322 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Stock Performance

AORT stock opened at $27.00 on Tuesday. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -385.66 and a beta of 1.24. Artivion has a 12 month low of $19.16 and a 12 month high of $48.25. The firm has a 50 day moving average of $25.78 and a two-hundred day moving average of $29.50.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The business had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. As a group, equities analysts anticipate that Artivion will post 0.45 EPS for the current fiscal year.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.